Romel Somwar

12.6k citations

91 papers · 8.6k indexed · 4 hit papers · h-index 39

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations

Papers in

Pulmonary and Respiratory Medicine 54
- Lung Cancer Treatments and Mutations 46
Oncology 32
- HER2/EGFR in Cancer Research 11
- Lung Cancer Research Studies 8

Co-authors: Mark G. Kris Gregory J. Riely William Pao Maureen F. Zakowski Vincent A. Miller Katerina Politi Amira Klip Harold Varmus
Journals: Clinical Cancer Research (11 papers)Journal of Thoracic Oncology (10 papers)Journal of Biological Chemistry (7 papers)Journal of Clinical Oncology (7 papers)Molecular Cancer Therapeutics (6 papers)
Partner nations: United States Canada Japan

In The Last Decade

Romel Somwar

85 papers receiving 8.4k citations

Hit Papers

align trajectories log scale

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 · 327 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 The Lancet Oncology
2006 Clinical Cancer Research
2005 PLoS Medicine
1999 Molecular and Cellular Biology

Peers

Countries citing papers authored by Romel Somwar

Since Specialization

Citations

This map shows the geographic impact of Romel Somwar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Romel Somwar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Romel Somwar more than expected).

Fields of papers citing papers by Romel Somwar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Romel Somwar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Romel Somwar. The network helps show where Romel Somwar may publish in the future.

Co-authors

The 25 scholars most cited alongside Romel Somwar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Romel Somwar Line = papers co-authored together Romel Somwar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas Journal of Clinical Investigation ·Nobuyuki MITSUI, Otto Molden, Daniel Cameron, 郭稚弧, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot S. Mundi, Yasumichi Kuwahara, Romel Somwar, Carla Maria Cerqueira da Silva, Andrea Califano, Elisa de Stanchina, Filemon S. Dela Cruz, Andrew L. Kung, Mrinal M. Gounder, Alex Kentsis	2025	0
2	Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy Cancer Discovery ·Nobuyuki MITSUI, Deborah E. Lipstadt, Otto Molden, 郭稚弧, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Carla Maria Cerqueira da Silva, Elisa de Stanchina, Filemon S. Dela Cruz, Andrew L. Kung, Mrinal M. Gounder, Alex Kentsis	2024	16
3	HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor Clinical Cancer Research ·Oliver Tiemann, Christopher A. Febres‐Aldana, Zebing Liu, Eamon D. Quick, 保夫芳賀, Raymond G. Dematteo, Daniela Virgínia Rios Dias de Medeiros, Inna Khodos, A. Steinsberg, Marissa S. Mattar, B G Brasil, Fang-Lei Lou, Irina Linkov, Ilirijana Mushkolaj, Elisa de Stanchina, Igor Odintsov, Marc Ladanyi, Romel Somwar	2024	6
4	Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification JCO Precision Oncology ·Arielle Elkrief, Igor Odintsov, Roger S. Smith, Morana Vojnic, Takuo Hayashi, Inna Khodos, Vladimir Markov, Zebing Liu, Daniela Virgínia Rios Dias de Medeiros, Alysse Jacobs, Michael Offin, Charles M. Rudin, Elisa de Stanchina, Gregory J. Riely, Romel Somwar, Marc Ladanyi	2024	3
5	Preclinical evaluation of targeted therapies for central nervous system metastases Disease Models & Mechanisms ·哲也石川, Tuba Yıldızdoğdu Dal, Leqi Su, 周玉森, Isao Miyazaki, Igor Odintsov, Romel Somwar	2024	3
6	2295P Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy Annals of Oncology ·Morana Vojnic, Igor Odintsov, Zhifeng Liu, Daniel C. Lu, Boboyorova Hayitoy Uchkun Qizi, Amir H. Ameri, Stephen Machnicki, Xiangjun Xiao, William W. Lockwood, Marc Ladanyi, Romel Somwar	2023	0
7	HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies Journal of Thoracic Oncology ·Hibiki Udagawa, Monique B. Nilsson, Jacqulyne Robichaux, Junqin He, Alissa Poteete, Hong Jiang, Simon Heeke, Yasir Y. Elamin, Yuji Shibata, Shingo Matsumoto, Kiyotaka Yoh, Shogo Okazaki, Takashi Masuko, Igor Odintsov, Romel Somwar, Marc Ladanyi, Kōichi Goto, John V. Heymach	2023	9
8	Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor Oncogenesis ·Theresa B. Smith, Hongjun Kang, John. Auteur de lettres Morris, Rosineide Rodrigues de Brito, Nathan Ungerleider, Isabelle St-Arnaud, Eder Andre Gubiani, Lee Spraggon, Romel Somwar, Krzysztof Moroz, David H. Drewry, Matthew E. Burow, Erik K. Flemington, Marc Ladanyi, Sean Bong Lee	2022	13
9	Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors Molecular Cancer Therapeutics ·Clare Keddy, Gheysa Mossini Balbino Dos Santos, Kristen L. Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A. Davare	2021	30
10	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer eLife ·Yusuke Inoue, Ana Nikolić, Torvac of Cambridge, Rocky Shi, Fraser Johnson, Alvin Liu, Marc Ladanyi, Romel Somwar, Marco Gallo, William W. Lockwood	2021	20
11	The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions Clinical Cancer Research ·Igor Odintsov, Daniela Virgínia Rios Dias de Medeiros, Bian Yi-lian, Carlos Enríquez G, Zebing Liu, Lukas Delasos, 裕彦杉田, Steven P. Glowinkowski, Morana Vojnic, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, V. Manandhar, Marc Ladanyi, Romel Somwar	2021	31
12	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers Journal of Thoracic Oncology ·Igor Odintsov, Marissa S. Mattar, Daniela Virgínia Rios Dias de Medeiros, Michael Offin, Evelyn Tubb, Lukas Delasos, Inna Khodos, Marina Asher, Donghan Wen, Natasha Rekhtman, Elisa de Stanchina, Gopinath Ganji, Marc Ladanyi, Romel Somwar	2021	21
13	Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor Clinical Cancer Research ·Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S. Bowman, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Achim A. Jungbluth, Marina Asher, Igor Odintsov, Theresa B. Smith, Michael P. LaQuaglia, Emily K. Slotkin, Christine A. Pratilas, Sean Bong Lee, Lee Spraggon, Marc Ladanyi	2020	24
14	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma Clinical Cancer Research ·Monika A. Davare, Pham Quoc Nguyen, Anupriya Agarwal, Jacob P. Wagner, Gomana M Abdelhameed, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W. Gilheeney, Evelyn Cai-Ni Chiew, Tom Mikkelson, Erwin G. Van Meir, Marc Ladanyi, Brian Druker	2018	37
15	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer Clinical Cancer Research ·Ken Suzawa, Michael Offin, Daniel Lu, Evelyn Tubb, Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	2018	83
16	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	2018	188
17	RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition Clinical Cancer Research ·Takuo Hayashi, Patrice Desmeules, Roger S. Smith, Alexander Drilon, Romel Somwar, Marc Ladanyi	2017	50
18	Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations Clinical Cancer Research ·Sardiman Gulo, Romel Somwar, James D. Joseph, Roger S. Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, 小川久雄, Eric S. Martin, Gregory J. Riely, Jason Harris, Shunqi Yan, Wei Ge, Jennifer Oliver, Rupal Patel, Pratik S. Multani, Marc Ladanyi, Alexander Drilon	2016	49
19	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer Clinical Cancer Research ·Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian Druker, Thomas O’Hare, Marc Ladanyi, Monika A. Davare	2015	128
20	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Clinical Cancer Research ·Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao Hit paper breakdown →	2006	664

About Romel Somwar

Romel Somwar is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Biochemistry, having authored 91 papers that have together received 8.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (46 papers), Metabolism, Diabetes, and Cancer (20 papers), PI3K/AKT/mTOR signaling in cancer (13 papers), Cancer Genomics and Diagnostics (12 papers), Protein Kinase Regulation and GTPase Signaling (11 papers), HER2/EGFR in Cancer Research (11 papers), Adipose Tissue and Metabolism (10 papers) and Lung Cancer Research Studies (8 papers). The work is most often cited by research in Oncology (3.4k citations), Pulmonary and Respiratory Medicine (4.0k citations), Cancer Research (1.5k citations), Molecular Biology (4.8k citations) and Biochemistry (286 citations). Romel Somwar has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Mark G. Kris, Gregory J. Riely, William Pao, Maureen F. Zakowski, Vincent A. Miller, Katerina Politi, Amira Klip, Harold Varmus, Gary Sweeney and Toolsie Ramlal. Their work appears in journals such as Clinical Cancer Research, Journal of Thoracic Oncology, Journal of Biological Chemistry, Journal of Clinical Oncology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact